A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a biotechnology company focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” The Cell-in-a-Box® technology is intended to be used as a platform upon which therapies for several types of cancer, including LAPC, will be developed. The current generation of our product candidate is referred to as “CypCaps™.” During the year ended April 30, 2024, we determined that research and development in the treatment of diabetes would no longer be pursued. On November 17, 2023, the Board formed the Strategic Scientific Committee (the “Scientific Committee”), chaired by Dr. Michael Abecassis. The Scientific Committee and our independent consultants are reviewing many of the risks relative to our business. In addition, the Board is reviewing risks associated with our development programs and our relationship with SG Austria Pte.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -11M | 23M | -17M | -4.3M | -4.2M | -3.6M |
| EPS | $0.72 | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-2.45 |
| Free Cash Flow | 0 | -3.0M | -2.2M | -3.8M | -4.1M | -3.3M |
| ROIC | -17.0% | 45.0% | -62.3% | -8.8% | -4.8% | -53.2% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.06 | 0.74 | - | - | 0.11 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -4.2M | -4.4M | -8.5M | -6.5M | -4.4M | -3.6M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -31.3% | 58.7% | -62.3% | - | - | -53.2% |
| Shares Outstanding | 10M | 7M | 10M | 8M | 16M | 21M |
PharmaCyte Biotech, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
PharmaCyte Biotech, Inc. trades at 0.2x trailing earnings, compared to its 15-year median P/E of 0.4x, suggesting it is currently Cheap relative to its historical range. Total shareholder yield (buybacks) is 5.7%.
PharmaCyte Biotech, Inc. (PMCB) has a current P/E ratio of 0.2, compared to its historical median P/E of 0.4. The stock is currently considered Cheap based on its historical valuation range.
PharmaCyte Biotech, Inc. (PMCB) has a 5-year average return on invested capital (ROIC) of -16.8%. This is below average and may indicate limited pricing power.
PharmaCyte Biotech, Inc. (PMCB) has a market capitalization of $7M. It is classified as a small-cap stock.
PharmaCyte Biotech, Inc. (PMCB) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 5.69%.
Based on historical P/E analysis, PharmaCyte Biotech, Inc. (PMCB) appears cheap. The current P/E of 0.2 is 43% below its historical median of 0.4.
PharmaCyte Biotech, Inc. (PMCB) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
PharmaCyte Biotech, Inc. (PMCB) generated $-3 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PharmaCyte Biotech, Inc. (PMCB) has a debt-to-equity ratio of 0.06. This indicates a conservatively financed balance sheet.
PharmaCyte Biotech, Inc. (PMCB) reported earnings per share (EPS) of $3.19 in its most recent fiscal year.
PharmaCyte Biotech, Inc. (PMCB) has a return on equity (ROE) of 58.7%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 15 years of financial data for PharmaCyte Biotech, Inc. (PMCB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PharmaCyte Biotech, Inc. (PMCB) has a book value per share of $7.09, based on its most recent annual SEC filing.